MedTrace Logo

Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT

NCT03336632 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-07-18

No results posted yet for this study

Summary

This study is to explore the efficacy and safety of introduction of chidamide in PTCy based GVHD prophylaxis in patients undergoing allogeneic PBSCT.

Conditions

  • Leukemia, Acute
  • MDS

Interventions

DRUG

Chidamide

20 mg orally, twice weekly from D-7 to D+14

DRUG

Cyclophosphamide

50 mg/Kg intravenously D+3, +4

DRUG

cyclosporine A

3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Ting Liu, MD · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-12-30
Completion
2021-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03336632 on ClinicalTrials.gov